Commerce Dashboard


Go Back


  • Leading global pharmaceutical company
  • More than 1,500 products various therapeutic categories
  • Over 43 state-of-the-art manufacturing facilities for API and formulations
  • Ranked amongst the top 10 most dispensed generic companies in North America

Cipla is a leading pharmaceutical from India with presence across the world. It was established in 1935 as Chemical Industrial & Pharmaceutical Laboratories Ltd and changed to its current name in 1984. The company has a vast portfolio with more than 1,500 products in the market. The company’s business is divided into three strategic units - APIs, respiratory and Cipla Global Access. Its largest market is India, followed by Africa and North America. Company’s total revenue reached Rs 17,132 crore (US$ 2.43 billion) in FY20.

Company Website:

Cipla – Caring for Life.

2020 Received approval for its Abbreviated New Drug Application (ANDA) for Albuterol Sulfate Inhalation Aerosol 90 mcg (base)/actuation
Acquired four key brands from Wanbury for up to Rs 89 crore (US$ 12.73 million) in order to strengthen its women’s health segment
2019 Acquired a novel and patented anti-infective product, Elores, from Venus Remedies Limited
Cipla received approval for generic version of Gilead Sciences, Inc’s Letairis
2018 Invagen (a Cipla subsidiary) entered into acquisition agreement with Avenue Therapeutics for specialty hospital business in the US
2017 Received approval for Q-TIB from World Health Organisation (WHO)
2016 Sold its stake in Chase
2014 Acquired minority stake in US-based Chase Pharma
2013 Acquired 100 per cent stake in Medpro South Africa
2005 Set up formulation facility in Baddi, Himachal Pradesh
2002 Set up four state-of-the-art manufacturing facilities in Goa
1999 Strategic partnership with Ranbaxy
1987 Launched several new products
1985 Approval from FDA for bulk drug manufacturing plants
1984 Name changed to Cipla
1952 Set up of first research division
1935 Incorporated in Mumbai, Maharashtra as Chemical Industrial & Pharmaceutical Laboratories Ltd


Updated: May, 2019

India plans to set up a nearly Rs 1 lakh crore (US$ 1.3 billion) fund to provide boost to companies to manufacture pharmaceutical ingredients domestically.